Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic
Genome editing using clustered regularly interspersed short palindromic repeats (CRISPR) and CRISPR-associated proteins offers the potential to facilitate safe and effective treatment of genetic diseases refractory to other types of intervention. Here, we identify some of the major challenges for cl...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Journal article |
Language: | English |
Published: |
BioMed Central
2017
|
_version_ | 1797085392786161664 |
---|---|
author | Nicol, D Eckstein, L Morrison, M Sherkow, J Otlowski, M Whitton, T Bubela, T Burdon, K Chalmers, D Chan, S Charlesworth, J Critchley, C Crossley, M de Lacey, S Dickinson, J Hewitt, A Kamens, J Kato, K Kleiderman, E Kodama, S Liddicoat, J Mackey, D Newson, A Nielsen, J Wagner, J McWhirter, R |
author_facet | Nicol, D Eckstein, L Morrison, M Sherkow, J Otlowski, M Whitton, T Bubela, T Burdon, K Chalmers, D Chan, S Charlesworth, J Critchley, C Crossley, M de Lacey, S Dickinson, J Hewitt, A Kamens, J Kato, K Kleiderman, E Kodama, S Liddicoat, J Mackey, D Newson, A Nielsen, J Wagner, J McWhirter, R |
author_sort | Nicol, D |
collection | OXFORD |
description | Genome editing using clustered regularly interspersed short palindromic repeats (CRISPR) and CRISPR-associated proteins offers the potential to facilitate safe and effective treatment of genetic diseases refractory to other types of intervention. Here, we identify some of the major challenges for clinicians, regulators, and human research ethics committees in the clinical translation of CRISPR-mediated somatic cell therapy. |
first_indexed | 2024-03-07T02:08:21Z |
format | Journal article |
id | oxford-uuid:9fc20fe2-3c18-4260-87ac-d1656af2850a |
institution | University of Oxford |
language | English |
last_indexed | 2024-03-07T02:08:21Z |
publishDate | 2017 |
publisher | BioMed Central |
record_format | dspace |
spelling | oxford-uuid:9fc20fe2-3c18-4260-87ac-d1656af2850a2022-03-27T02:00:19ZKey challenges in bringing CRISPR-mediated somatic cell therapy into the clinicJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9fc20fe2-3c18-4260-87ac-d1656af2850aEnglishSymplectic Elements at OxfordBioMed Central2017Nicol, DEckstein, LMorrison, MSherkow, JOtlowski, MWhitton, TBubela, TBurdon, KChalmers, DChan, SCharlesworth, JCritchley, CCrossley, Mde Lacey, SDickinson, JHewitt, AKamens, JKato, KKleiderman, EKodama, SLiddicoat, JMackey, DNewson, ANielsen, JWagner, JMcWhirter, RGenome editing using clustered regularly interspersed short palindromic repeats (CRISPR) and CRISPR-associated proteins offers the potential to facilitate safe and effective treatment of genetic diseases refractory to other types of intervention. Here, we identify some of the major challenges for clinicians, regulators, and human research ethics committees in the clinical translation of CRISPR-mediated somatic cell therapy. |
spellingShingle | Nicol, D Eckstein, L Morrison, M Sherkow, J Otlowski, M Whitton, T Bubela, T Burdon, K Chalmers, D Chan, S Charlesworth, J Critchley, C Crossley, M de Lacey, S Dickinson, J Hewitt, A Kamens, J Kato, K Kleiderman, E Kodama, S Liddicoat, J Mackey, D Newson, A Nielsen, J Wagner, J McWhirter, R Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic |
title | Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic |
title_full | Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic |
title_fullStr | Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic |
title_full_unstemmed | Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic |
title_short | Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic |
title_sort | key challenges in bringing crispr mediated somatic cell therapy into the clinic |
work_keys_str_mv | AT nicold keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT ecksteinl keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT morrisonm keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT sherkowj keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT otlowskim keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT whittont keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT bubelat keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT burdonk keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT chalmersd keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT chans keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT charlesworthj keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT critchleyc keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT crossleym keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT delaceys keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT dickinsonj keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT hewitta keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT kamensj keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT katok keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT kleidermane keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT kodamas keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT liddicoatj keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT mackeyd keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT newsona keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT nielsenj keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT wagnerj keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic AT mcwhirterr keychallengesinbringingcrisprmediatedsomaticcelltherapyintotheclinic |